Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration

Future Med Chem. 2017 May;9(8):765-780. doi: 10.4155/fmc-2017-0014. Epub 2017 May 12.

Abstract

Melatonin is an indoleamine produced mainly in the pineal gland. The natural decline of melatonin levels with aging strongly contributes to the development of neurodegenerative disorders. Pleiotropic actions displayed by melatonin prevent several processes involved in neurodegeneration such as neuroinflammation, oxidative stress, excitotoxicity and/or apoptosis. This review focuses on a number of melatonin hybrids resulting from the juxtaposition of tacrine, berberine, tamoxifen, curcumin, N,N-dibenzyl(N-methyl)amine, among others, with potential therapeutic effects for the treatment of neurodegenerative diseases.

Keywords: Alzheimer's disease; MTDLs; antioxidant therapy; hybrid compounds; melatonin; multitarget-directed ligands; neurodegeneration.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Design*
  • Humans
  • Melatonin / chemical synthesis
  • Melatonin / chemistry
  • Melatonin / therapeutic use
  • Molecular Structure
  • Neurodegenerative Diseases / drug therapy*
  • Neuroprotective Agents / chemical synthesis
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / therapeutic use*

Substances

  • Neuroprotective Agents
  • Melatonin